A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer Clinical Trial

— OECTAPGAMPC  

Official title:

A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02863367
• Other study ID #: AHEAD-HBP001
• Status: Not yet recruiting
• Phase: Phase 2
• First received: July 26, 2016
• Last updated: August 7, 2016
• Start date: August 2016
• Est. completion date: December 2017

Study information

• Verified date: July 2016
• Source: Tianjin Medical University Cancer Institute and Hospital
• Contact: Hao Ji Hui, PhD
• Phone: 022-23340123
• Email: renhe[@]tjmuch.com
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Evaluate the efficacy and safety of Apatinib (500mg/d) with gemcitabine(1000mg/m2) in advanced metastatic pancreatic cancer.

Description:

This test is a single center, one-armed exploratory clinical research, aimed at the evaluation the efficacy and safety of Apatinib with Gemcitabine in the patients with advanced metastatic pancreatic cancer.

This study plan in Tianjin Medical University Cancer Institute and Hospital.From launched in July 2016, this research intends to recruit the end time about as of December 2017, is expected to the end of the test time is in December 2017.

If do not have the appearance of the following circumstances, such as the subjects out of informed consent, drug toxicity tolerance or the researchers think that do not fit for further test, each subject research and treatment time is expected until imaging of tumor progression.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: December 2017
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age of patients ranges from 18 to 75 years old.

2. Histologically or cytologic confirmed advanced metastatic pancreatic cancer (Exclusion of islet cell tumor ) .

3. Must not received radiotherapy, chemotherapy or experimental treatment for advanced metastatic pancreatic cancer. Transfer of postoperative recurrence of patients with advanced pancreatic cancer can also be into the group.

4. Karnofsky Performance Status Scale (KPS) =70.

5. The first confirmed date of advanced metastatic pancreatic cancer not more than 6 weeks before starting treatment.

6. No jaundice symptoms. Obviously abdominal water or have symptoms, need a drainage in advance. Don't need to adjust the analgesic therapy.

7. Adequate hematologic functions :Hemoglobin (HGB) = 90g/dL, Platelets (PLT) = 100×10^9/L, the absolute number of Neutrophil (ANC) = 1.5×10^9/L.

8. Adequate hepatic, renal, heart functions :Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5×the upper limit of normal (ULN).If liver metastases, AST and ALT =5.0×the ULN. Total bilirubin within the ULN. Serum Creatinine within the ULN, or creatinine clearance = 60 mL/min.

9. Blood coagulation test results: Prothrombin Time (PT) and Partial Thromboplastin Time (PPT) within ±15% of the normal.

10. No clinically significant abnormal urine analysis results.

11. Women with pregnancy or lactation, or fertility but during treatment and 6 months after treatment of termination unwilling or unable to use effective contraception to avoid pregnancy patients with male or female

12. Signed and dated informed consent of document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment

13. Patient consent and well compliance, scheduled to accept the visits, treatment, laboratory tests and other study procedures

Exclusion Criteria:

1. Patients with the known brain metastases.

2. Patients with locally advanced disease only.

3. Decline in serum albumin (ALB) = 20% from the screening visit to cycle 1 day 1 prior to the 72 hours.

4. Over the past five years has a history of malignant tumors (including chronic leukemia). Patients with carcinoma in situ or basal cell carcinoma or squamous cell skin cancer can be selected.

5. With need of systemic treatment activity, unable to control bacterial, viral or fungal infections

6. Known HIV infection, or active hepatitis B or hepatitis C virus (HCV) infection.

7. A major surgery (not include the diagnostic surgery) not more than 4 weeks before starting treatment.

8. In the period of 6 months before starting treatment, Patients with myocardial infarction, severe or unstable angina, coronary artery and peripheral artery bypass grafting, New York heart association (NYHA) three - four level cardiac failure, out of control of high blood pressure, Patients with clinical significance of arrhythmia or abnormal electrocardiogram (ECG), cerebrovascular accident, transient ischemic attack, epilepsy, or with clinical significance of arrhythmia or a history of abnormal electrocardiogram (ECG).

9. Has any study drug or its accessories history of allergies or allergic reactions, or patients showed this product or controlled drug prescribing information "contraindications or special warnings and precautions" section Outlines of events.

10. The history of connective tissue disease (such as lupus, scleroderma, nodular arteritis).

11. Has a history of interstitial pneumonia, slowly progressive dyspnea and cough, sarcoidosis, and silicosis, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, or a variety of allergies.

12. Could damage patient safety or the integrity of the data to any situation, including severe medical risk factors, medical events and laboratory abnormalities or mental illness;

13. Enter any other clinical study, some involved in drug test, or may interfere with the study in the program evaluation;

14. The patient is not willing to or cannot meet research program, or plans for vacation during the research and treatment more than 7 days or seven days;

15. The investigator think that the person doesn't fit into the study.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Metastatic Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• Apatinib
Apatinib:500 mg,po,qd, d1-14, every 3 week
• Gemcitabine
Gemcitabine:1000mg/m²,vein input 30-40,d1,d8,every 3 week

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Tianjin Medical University Cancer Institute and Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate (ORR)		1 years	No
Secondary	progression-free survival (PFS)		1 years	No
Secondary	Overall Survival (OS)		1 years	No
Secondary	Life Quality Score (QoL)		1 years	No
Secondary	Disease Control Rate (DCR)		1 years	No
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0		1 years	No